Supplementary Data from FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Donna Przepiorka, Robert Q. Le, Alexei Ionan,Ruo-Jing Li,Ying-Hong Wang,Ramadevi Gudi, Soumya Mitra,Jonathon Vallejo,Olanrewaju O. Okusanya,Lian Ma,Yuching Yang,Paresma Patel, Djelila Mezaache, Rakhi Shah,Anamitro Banerjee, Sherita McLamore,Adam N. Maung,Kirsten B. Goldberg,Richard Pazdur,Marc R. Theoret,R. Angelo De Claro

crossref（2023）

引用 0|浏览14

暂无评分

摘要

Supplementary Data from FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要